HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- (2- hydroxy- 2- methylpropyl)- 3- (1- (4- (1- methyl- 2- oxo- 1,2- dihydropyridin- 4- yl)phenyl)ethyl)- 6- phenyl- 1,3- oxazinan- 2- one

an 11beta-hydroxysteroid dehydrogenase 1 inhibitor; structure in first source

Also Known As:

BI 135585

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - 6-(2-hydroxy-2-methylpropyl)-3-(1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one: 2
  - Oxazines: 9
    - 6-(2-hydroxy-2-methylpropyl)-3-(1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one: 2

Experts

1.	Freude, S: 1 article (05/2016)
2.	Graefe-Mody, U: 1 article (05/2016)
3.	Hamilton, B: 1 article (05/2016)
4.	Heise, T: 1 article (05/2016)
5.	Huang, F: 1 article (05/2016)
6.	Jungnik, A: 1 article (05/2016)
7.	Rauch, T: 1 article (05/2016)
8.	Schölch, C: 1 article (05/2016)
9.	Woerle, H-J: 1 article (05/2016)
10.	Claremon, David A: 1 article (01/2015)

Related Diseases

1.

Type 2 Diabetes Mellitus (MODY)

05/01/2016 - "The single-dose study included open-label administration of 200 mg BI 135585 in healthy volunteers, while in the multiple-dose study, we carried out randomized, double-blind administration of 5-200 mg BI 135585 or placebo once daily over 14 days in patients with type 2 diabetes (T2DM). "
01/05/2015 - "Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes."

Related Drugs and Biologics

1.	Oxidoreductases (Dehydrogenase)